Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.
AGR
Biomarker
Neoadjuvant
UTUC
Urothelial
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
21
07
2020
accepted:
01
10
2020
pubmed:
18
10
2020
medline:
12
1
2022
entrez:
17
10
2020
Statut:
ppublish
Résumé
The accurate selection of patients who are most likely to benefit from neoadjuvant chemotherapy is an important challenge in oncology. Serum AGR has been found to be associated with oncological outcomes in various malignancies. We assessed the association of pre-therapy serum albumin-to-globulin ratio (AGR) with pathologic response and oncological outcomes in patients treated with neoadjuvant platin-based chemotherapy followed by radical nephroureterectomy (RNU) for clinically non-metastatic UTUC. We retrospectively included all clinically non-metastatic patients from a multicentric database who had neoadjuvant platin-based chemotherapy and RNU for UTUC. After assessing the pretreatment AGR cut-off value, we found 1.42 to have the maximum Youden index value. The overall population was therefore divided into two AGR groups using this cut-off (low, < 1.42 vs high, ≥ 1.42). A logistic regression was performed to measure the association with pathologic response after NAC. Univariable and multivariable Cox regression analyses tested the association of AGR with OS and RFS. Of 172 patients, 58 (34%) patients had an AGR < 1.42. Median follow-up was 26 (IQR 11-56) months. In logistic regression, low AGR was not associated with pathologic response. On univariable analyses, pre-therapy serum AGR was neither associated with OS HR 1.15 (95% CI 0.77-1.74; p = 0.47) nor RFS HR 1.48 (95% CI 0.98-1.22; p = 0.06). These results remained true regardless of the response to NAC. Pre-therapy low serum AGR before NAC followed by RNU for clinically high-risk UTUC was not associated with pathological response or long-term oncological outcomes. Biomarkers that can complement clinical factors in UTUC are needed as clinical staging and risk stratification are still suboptimal leading to both over and under treatment despite the availability of effective therapies.
Identifiants
pubmed: 33067726
doi: 10.1007/s00345-020-03479-3
pii: 10.1007/s00345-020-03479-3
pmc: PMC8332553
doi:
Substances chimiques
Globulins
0
Serum Albumin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2567-2577Informations de copyright
© 2020. The Author(s).
Références
Eur J Cancer. 2009 Dec;45(18):3291-7
pubmed: 19615885
Urol Oncol. 2016 Nov;34(11):484.e1-484.e8
pubmed: 27341738
Int J Clin Oncol. 2020 Jun;25(6):1037-1054
pubmed: 32206939
Chin Med J (Engl). 2013;126(8):1464-8
pubmed: 23595378
Urol Oncol. 2010 Jul-Aug;28(4):389-400
pubmed: 20610277
Eur Urol. 2011 Oct;60(4):776-83
pubmed: 21798659
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
Clin Cancer Res. 2010 Sep 1;16(17):4461-7
pubmed: 20651056
Eur Urol. 2007 Dec;52(6):1601-9
pubmed: 17919807
Cancer Manag Res. 2018 Oct 17;10:4695-4708
pubmed: 30410403
Eur Urol. 2010 Oct;58(4):574-80
pubmed: 20637540
Radiat Oncol. 2010 Jun 03;5:47
pubmed: 20525293
J Urol. 2020 Jun;203(6):1101-1108
pubmed: 31898919
N Engl J Med. 1999 Feb 11;340(6):448-54
pubmed: 9971870
BJU Int. 2013 Aug;112(4):453-61
pubmed: 23464979
Nat Rev Urol. 2011 Jul 05;8(8):440-7
pubmed: 21727942
Clin Genitourin Cancer. 2018 Jun;16(3):e655-e661
pubmed: 29366633
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Onco Targets Ther. 2018 Mar 15;11:1423-1432
pubmed: 29588597
Eur Urol. 2012 Feb;61(2):245-53
pubmed: 21975249
Breast. 2019 Apr;44:33-38
pubmed: 30611095
J Cancer. 2017 Oct 23;8(19):4002-4010
pubmed: 29187875
J Cancer. 2018 Jun 12;9(13):2341-2348
pubmed: 30026830
PLoS One. 2015 Dec 17;10(12):e0144961
pubmed: 26681341
Dis Esophagus. 2020 Jun 15;33(6):
pubmed: 31676907
Gastric Cancer. 2020 May;23(3):540-549
pubmed: 32072387
Onco Targets Ther. 2017 May 22;10:2655-2664
pubmed: 28579803
Clin Genitourin Cancer. 2015 Aug;13(4):e229-e233
pubmed: 25777682
Am J Cancer Res. 2015 Aug 15;5(9):2856-64
pubmed: 26609491
Oncology. 2018;95(5):270-280
pubmed: 29996133
Eur Urol. 2014 Jan;65(1):210-7
pubmed: 22579047
Lancet. 2020 Apr 18;395(10232):1268-1277
pubmed: 32145825
APMIS. 2010 Dec;118(12):941-8
pubmed: 21091775
Nat Commun. 2019 Jul 5;10(1):2977
pubmed: 31278255
BJU Int. 2009 Feb;103(3):307-11
pubmed: 18990163
Clin Genitourin Cancer. 2018 Oct;16(5):e1059-e1068
pubmed: 29980449
Eur Urol. 2021 Jan;79(1):62-79
pubmed: 32593530
Int J Mol Sci. 2019 Feb 13;20(4):
pubmed: 30781730